Ascendis Pharma A/S (NASDAQ:ASND) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research note published on Tuesday morning.

A number of other brokerages have also recently weighed in on ASND. Citigroup upped their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Finally, TD Cowen raised their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Stock Down 1.4 %

NASDAQ ASND opened at $124.28 on Tuesday. Ascendis Pharma A/S has a twelve month low of $90.13 and a twelve month high of $161.00. The stock has a market cap of $7.54 billion, a P/E ratio of -13.35 and a beta of 0.66. The company’s 50-day simple moving average is $132.15 and its 200 day simple moving average is $132.80.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Erste Asset Management GmbH bought a new position in Ascendis Pharma A/S in the 3rd quarter valued at $2,936,000. Acuta Capital Partners LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at $3,136,000. Finepoint Capital LP boosted its holdings in Ascendis Pharma A/S by 0.4% in the third quarter. Finepoint Capital LP now owns 190,072 shares of the biotechnology company’s stock valued at $28,380,000 after acquiring an additional 800 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Ascendis Pharma A/S by 49.5% in the third quarter. The Manufacturers Life Insurance Company now owns 71,307 shares of the biotechnology company’s stock worth $10,647,000 after purchasing an additional 23,595 shares during the period. Finally, Loomis Sayles & Co. L P raised its holdings in Ascendis Pharma A/S by 35.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after purchasing an additional 48,120 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.